16 September 2026 editorial review · Trial
Single-center phase 3 islet transplantation in non-uremic T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT01897688; COMPLETED; updated 2026-06-18; enrollment 10 (ACTUAL); results posted.
Endpoint comparison: Safety and Feasibility of Islet Transplantation to Treat Type-1 Diabetes (T1D) (Two years after the final islet transplant.).
Sources for this record: NCT01897688: Single-center phase 3 islet transplantation in non-uremic T1D (registry); NCT01897688 posted results: participant flow, outcome measures and adverse events (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.